Heron Therapeutics
HRTX
199 hedge funds and large institutions have $2.33B invested in Heron Therapeutics in 2019 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 78 increasing their positions, 51 reducing their positions, and 16 closing their positions.
169% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 16
53% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 51
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more capital invested
Capital invested by funds: $1.69B → $2.33B (+$635M)
11% more funds holding
Funds holding: 180 → 199 (+19)
3% more call options, than puts
Call options by funds: $4.93M | Put options by funds: $4.8M
4.56% less ownership
Funds ownership: 114.55% → 109.99% (-4.6%)
Top Buyers
| 1 |
Franklin Resources
San Mateo,
California
|
+$44.8M |
| 2 |
D.E. Shaw & Co
New York
|
+$26.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.9M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$19.4M |
| 5 |
Goldman Sachs
New York
|
+$18.8M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.4M |
| 2 |
BM
Bridger Management
New York
|
-$15.6M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$11M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$9.36M |
| 5 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$6.96M |
HRTX Hedge Fund Activity: Q4 2019 in Review
199 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2019, worth a combined $2.33B — up 38% from $1.69B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new HRTX positions and 16 closed out — a net gain of 27 holders — while 78 added to existing stakes and 51 trimmed.
The largest buyer was Franklin Resources, adding an estimated $44.8M. The largest seller was Fidelity Investments, cutting an estimated $42.4M.
- 199 institutional investors held Heron Therapeutics (HRTX) as of Q4 2019, up from 180 in Q3 2019.
- Funds reported $2.33B of Heron Therapeutics stock for Q4 2019, up 38% quarter-over-quarter.
- 43 funds opened new Heron Therapeutics positions in Q4 2019 and 16 closed out, a net change of +27 holders.
- The largest Heron Therapeutics buyer in Q4 2019 was Franklin Resources, an estimated $44.8M added.
- The largest Heron Therapeutics seller in Q4 2019 was Fidelity Investments, an estimated $42.4M sold.
Based on aggregated 13F filings for Q4 2019.